Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis - PubMed (original) (raw)
Meta-Analysis
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis
Phei Ching Lim et al. Daru. 2022 Jun.
Abstract
Purpose: Tocilizumab has shown equivocal outcomes in reducing mortality in COVID-19. The corticosteroids appear to be an affordable alternative to tocilizumab. This study aims to estimate the efficacy of tocilizumab and the corticosteroids particularly dexamethasone and methylprednisolone and to identify possible determinants of their efficacy.
Methods: Five electronic databases were searched for studies involving tocilizumab, dexamethasone, and methylprednisolone in treating COVID-19. We included case-control and randomized or partially randomized trials. Meta-regression for patient baseline characteristics, co-medications, and tocilizumab dose regimens was performed to identify contributing factors to drug efficacy.
Results: Thirteen randomized controlled trials (RCTs) and twenty-four case-control studies were included in our meta-analysis involving 18,702 patients. Meta-analysis among the RCTs showed that a summary estimate favoring mortality reduction (OR 0.71, 95%CI 0.55 - 0.92) contributed mainly by tocilizumab and dexamethasone. Among case-control studies, meta-analysis showed mortality reduction (OR 0.52, 95%CI 0.36 - 0.75) contributed by tocilizumab and tocilizumab-methylprednisolone combination. Methylprednisolone alone did not reduce mortality except for one study involving high dose pulse therapy. Meta-analysis also found that all three drugs did not significantly reduce mechanical ventilation (OR 0.72, 95%CI 0.32 - 1.60).
Conclusion: Tocilizumab and dexamethasone emerge as viable options in reducing mortality in severe COVID-19 patients. A tocilizumab-corticosteroid combination strategy may improve therapeutic outcome in cases where single therapy fails.
Keywords: COVID-19; Dexamethasone; Meta-analysis; Methylprednisolone; Tocilizumab.
© 2022. Springer Nature Switzerland AG.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1
Flow chart for study screening and selection according to PRISMA guidelines
Fig. 2
Forest plot for the effect for all treatments (tocilizumab, methylprednisolone, and dexamethasone) on mortality in randomised controlled trials
Fig. 3
Forest plot for the effect of all treatments (tocilizumab, methylprednisolone, and dexamethasone) on mortality in case–control studies
Fig. 4
Forest plot for the effect of tocilizumab alone on mortality
Fig. 5
Forest plot for effect of all treatments (tocilizumab, methylprednisolone, and dexamethasone) on the event of invasive mechanical ventilation
Fig. 6
Funnel plot for (a) randomised clinical trials, and (b) case–control studies included in the meta-analysis
Similar articles
- Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.
Wagner C, Griesel M, Mikolajewska A, Metzendorf MI, Fischer AL, Stegemann M, Spagl M, Nair AA, Daniel J, Fichtner F, Skoetz N. Wagner C, et al. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2. Cochrane Database Syst Rev. 2022. PMID: 36385229 Free PMC article. - Systemic corticosteroids for the treatment of COVID-19.
Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, Kley K, Metzendorf MI, Fischer AL, Kopp M, Stegemann M, Skoetz N, Fichtner F. Wagner C, et al. Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963. Cochrane Database Syst Rev. 2021. PMID: 34396514 Free PMC article. Updated. - Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma.
Kirkland SW, Cross E, Campbell S, Villa-Roel C, Rowe BH. Kirkland SW, et al. Cochrane Database Syst Rev. 2018 Jun 2;6(6):CD012629. doi: 10.1002/14651858.CD012629.pub2. Cochrane Database Syst Rev. 2018. PMID: 29859017 Free PMC article. - Systemic treatments for metastatic cutaneous melanoma.
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. - SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. Kreuzberger N, et al. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. Cochrane Database Syst Rev. 2021. PMID: 34473343 Free PMC article.
Cited by
- Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.
Qin Z, Li Y, Sun W, Lu Y, Zhang N, Yang R, Liu Y, Tang L, Liu Q. Qin Z, et al. Front Public Health. 2023 Oct 2;11:1198987. doi: 10.3389/fpubh.2023.1198987. eCollection 2023. Front Public Health. 2023. PMID: 37920591 Free PMC article. - Association of Polymorphisms of IL-6 Pathway Genes (IL6, IL6R and IL6ST) with COVID-19 Severity in an Amazonian Population.
Rodrigues FBB, da Silva R, Santos EFD, de Brito MTFM, da Silva ALS, de Meira Leite M, Póvoa da Costa F, de Nazaré do Socorro de Almeida Viana M, de Sarges KML, Cantanhede MHD, Veríssimo AOL, Carvalho MDS, Henriques DF, Silva CPD, Costa IB, Nunes JAL, Costa IB, Viana GMR, Queiroz MAF, Lima SS, Lopes JDC, Torres MKDS, Vallinoto IMVC, Bichara CDA, Vallinoto ACR, Santos EJMD. Rodrigues FBB, et al. Viruses. 2023 May 19;15(5):1197. doi: 10.3390/v15051197. Viruses. 2023. PMID: 37243282 Free PMC article. - Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
Elhazmi A, Rabie AA, Al-Omari A, Mufti HN, Sallam H, Alshahrani MS, Mady A, Alghamdi A, Altalaq A, Azzam MH, Sindi A, Kharaba A, Al-Aseri ZA, Almekhlafi GA, Tashkandi W, Alajmi SA, Faqihi F, Alharthy A, Al-Tawfiq JA, Melibari RG, Arabi YM. Elhazmi A, et al. J Clin Med. 2023 Mar 16;12(6):2301. doi: 10.3390/jcm12062301. J Clin Med. 2023. PMID: 36983304 Free PMC article. - New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.
Nada H, Choi Y, Kim S, Jeong KS, Meanwell NA, Lee K. Nada H, et al. Signal Transduct Target Ther. 2024 Dec 6;9(1):341. doi: 10.1038/s41392-024-02036-3. Signal Transduct Target Ther. 2024. PMID: 39638817 Free PMC article. Review. - COVID-19 Case Management Outcomes Amongst Diabetes and Hypertensive Patients in the United Arab Emirates: A Prospective Study.
Alkhemeiri A, Al Zaabi S, Lakshmanan J, El-Khatib Z, Awofeso N. Alkhemeiri A, et al. Int J Environ Res Public Health. 2022 Nov 30;19(23):15967. doi: 10.3390/ijerph192315967. Int J Environ Res Public Health. 2022. PMID: 36498037 Free PMC article.
References
- The John Hopkins Coronavirus Resource Center. Cumulative cases. In: The John Hopkins Coronavirus Resource Center. The John Hopkins and Medicine System. 2021. https://coronavirus.jhu.edu/data/cumulative-cases. Accessed 15 January 2021.
- Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources